Competition & Markets Authority
Pharmaceutical merger cleared by CMA
The CMA has cleared the anticipated purchase of gene therapy company Spark Therapeutics by pharmaceutical company Roche Holdings.
Both companies develop treatments that aim to prevent bleeding in patients with Haemophilia A, a genetic blood disorder. The Competition and Markets Authority (CMA) has been examining whether the deal could negatively affect the future treatment choices available to the NHS, doctors and patients.
Roche supplies a drug called Hemlibra, a relatively-recent market entrant that has already become recognised as an important and innovative medicine for patients in the UK. Spark is in the process of developing a gene therapy treatment for Haemophilia A that is expected to compete with Hemlibra in future.
The CMA’s initial Phase 1 investigation found that the supply of Haemophilia A treatments is a developing sector in which a number of suppliers are in the process of bringing new products to market.
While gene therapy treatments are likely to compete with Roche’s Hemlibra in future, the CMA found that Spark is not the only supplier developing a gene therapy treatment and that its products are not currently considered to hold any particular clinical or commercial advantages over those being developed by other suppliers.
The CMA’s investigation also found that there are several innovative non-gene therapy products under development that are likely to become viable alternatives to Roche and Spark’s treatments.
The CMA therefore found that the deal between Roche and Spark would not negatively affect competition because UK health services and patients will still have an adequate choice of alternatives.
The deal is also being investigated by the US Federal Trade Commission and the 2 authorities have cooperated closely.
More information can be found on the CMA’s Roche Holdings/Spark Therapeutics inquiry page.
Latest News from
Competition & Markets Authority
Second firm admits illegal role in agreement for essential drug24/01/2020 10:10:00
Drug company Tiofarma has admitted that it took part in an agreement that resulted in significant price hikes for an essential medicine.
CMA consults on annual plan24/01/2020 09:10:00
The CMA has launched a consultation on its annual plan for 2020/21
Guitar maker fined £4.5m for illegally preventing price discounts23/01/2020 09:20:00
The CMA has fined Fender Europe £4.5 million for breaking competition law by preventing online discounting for its guitars.
CMA publishes loyalty penalty update22/01/2020 12:20:00
The CMA has reported on the progress made in tackling the loyalty penalty that impacts millions of people.
Court of Appeal upholds CMA decision on online sales21/01/2020 14:43:00
The Court of Appeal has upheld the CMA’s finding that a golf equipment supplier acted illegally by banning online sales of its products.
Facebook and eBay pledge to combat trading in fake reviews09/01/2020 09:20:00
Following action from the CMA, Facebook and eBay have committed to combatting the trade of fake and misleading reviews on their sites.
Illumina/PacBio abandon merger03/01/2020 10:20:00
Illumina has abandoned its anticipated $1.2 billion takeover of PacBio after an in-depth CMA merger probe highlighted serious competition concerns.
LN-Gaiety’s purchase of MCD cleared by CMA20/12/2019 12:20:00
An in-depth CMA investigation has found that Live Nation-Gaiety’s proposed purchase of MCD does not raise competition concerns.